How safe is CBD?

Many people are concerned with the safety of CBD use, and worry about the current lack of FDA approval for most CBD products currently on the market (the drug Epidiolex conatins CBD and was approved by the FDA for treatment of severe epileptic seizures). As we've mentioned in previous posts, the World Health Organization has... Continue Reading →

Cannabidiol–antiepileptic drug comparisons and interactions in experimentally induced seizures in rats.

Abstract A comparison of the anticonvulsant and neurotoxic effects of cannabidiol (CBD), delta 9tetrahydrocannabinol, cannabinol and antiepileptic drugs (phenytoin, phenobarbital, carbamazepine, chlordiazepoxide, clonazepam, ethosuximide and trimethadione) was made in rats. Median effective potencies (ED 50 values) for maximal electroshock, audiogenic seizures and TD50 values for a rotor rod neurotoxicity test were calculated. Additionally, the interactive... Continue Reading →

Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures.

Abstract Cannabis sativa has been associated with contradictory effects upon seizure states despite its medicinal use by numerous people with epilepsy. We have recently shown that the phytocannabinoid cannabidiol (CBD) reduces seizure severity and lethality in the well-established in vivo model of pentylenetetrazole-induced generalised seizures, suggesting that earlier, small-scale clinical trials examining CBD effects in... Continue Reading →

Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo.

Abstract Plant-derived cannabinoids (phytocannabinoids) are compounds with emerging therapeutic potential. Early studies suggested that cannabidiol (CBD) has anticonvulsant properties in animal models and reduced seizure frequency in limited human trials. Here, we examine the antiepileptiform and antiseizure potential of CBD using in vitro electrophysiology and an in vivo animal seizure model, respectively. CBD (0.01-100 muM)... Continue Reading →

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.

Abstract Severe childhood epilepsies are characterized by frequent seizures, neurodevelopmental delays, and impaired quality of life. In these treatment-resistant epilepsies, families often seek alternative treatments. This survey explored the use of cannabidiol-enriched cannabis in children with treatment-resistant epilepsy. The survey was presented to parents belonging to a Facebook group dedicated to sharing information about the... Continue Reading →

Up ↑